Leading Pharma industry experts plan to be at the Pharma Market Research Conference which takes place on February 7-8 at the Hilton Parsippany Hotel in New Jersey.
Ahmedabad based Contract Research and Manufacturing Services (CRAMS) major Dishman Pharmaceuticals and Chemicals Ltd has entered into a strategic alliance with California based biotechnology firm Codexis, Inc. that will allow Dishman to use of Codexis' proprietary enzymatic biocatalysis technology to manufacture intermediates and active pharmaceutical intermediates (APIs).
The Indian drug industry could make huge gains as over $70 billion worth of drugs are expected to go off patent in the US, the world’s largest pharma market, in the next three years.
3SBio Inc, a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis.
Like pharma giants Pfizer, Eli Lilly and Merck & Co, US biotechnology major Biogen Idec also doesn’t want to miss the India opportunity.
Myriad Pharmaceuticals Inc agreed to buy Javelin Pharmaceuticals Inc in an all-stock deal worth about $96 million, snapping up Javelin's lead post-operative pain drug, Dyloject.
India's pharmaceutical sector has stepped up its research & development expenditure in a bid to capture a larger market share in highly regulated and emerging markets.
Cancer focused Biotechnology Company Gloucester Pharmaceuticals Inc. has agreed to be acquired by New Jersey firm Celgene Corp. for approximately $640 million, with $340 million paid in cash up front.
World’s second-largest generic drug maker Mylan, which held a majority stake in Ahmedabad based Concord Biotech through its subsidiary
The assurance of cutting greenhouse gas emissions by China a source of cheap raw material has sent jitters across the pharmaceutical industry which apprehends that it will lead to drug rates shooting up.
The government has decided to adopt a two-pronged approach to step up the pace of pharmaceutical research in the country. This will include tie-ups with reputed overseas universities for collaborative research and education programmes, as well as setting up innovation centres at the six new National Institutes of Pharmaceutical Education and Research (Nipers), which are proposed to be set up.
For the first time companies of the Central Germany chemical and biotechnology industry presented their innovations and products to India at The CPhI India 2009 . This has been facilitated by Germany's Federal Ministry of Education and Research (BMBF) under the two year campaign "Research in Germany – Land of Ideas" A total of five companies from the German States Saxony-Anhalt and Saxony will explore research, development and market opportunities in India.
Launches RECOMBINATE a genetically engineered, non-plasma-derived FVIII bringing advanced care to people with Hemophilia in India. Baxter India Private Limited, a wholly owned subsidiary of Baxter International Inc., the global leader in Hemophilia care today announced the launch of RECOMBINATE in India. RECOMBINATE, a genetically engineered non plasma-derived recombinant factor (rFVIII) through increased viral safety and uninterrupted supply, represents a significant step forward in raising the standards of care for people with Hemophilia in India. RECOMBINATE is indicated for the prevention and control of hemorrhagic episodes and for the preoperative management of people with Hemophilia A.
When one door closes, another opens. What Alexander Graham Bell said ages ago makes perfect sense for the medicinemakers today. With developed markets, for long a lucrative source of revenue, crimped by slowdown, pharma firms are turning attention to the galloping seven in the developing world — Brazil, Russia, India, China (or the famed BRIC), and Mexico, Indonesia, and Turkey –or the E7 — as the new El Dorado.
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts.
Momentum is building for the early December staging in Mumbai of the third CPhI India and second P-MEC India pharma ingredients, services and technologies event. A combined total of over 600 exhibitors from over 80 countries are expected at the Bombay Exhibition Centre for the 2009 events, being held on 1 – 3 December.
The fourth edition of the biotechnology investor forum, BioInvest 2009, organized by The Association of Biotechnology Led Entrepreneurs (ABLE) will be held in Mumbai on November 5. The event has been designed to ascertain the future of investment and partnerships in the country’s biosciences space.
India has become a major hub for pharmaceutical companies of the world. An India-strategy is a must for all western companies and is often mandated by their managements.
Novel seeds for the challenges of the changing environment.Today, India's leading life sciences company, Avesthagen Limited announced the formation of a joint venture (JV) “Atash Seeds Private Limited” with Limagrain, an international cooperative group.